Sorafenib in advanced hepatocellular carcinoma

Cited by (1,037)

Items 1,001–1,037 of 1,037

1. When are ‘positive’ clinical trials in oncology truly positive?
   Ocana, A., Tannock, I. F. · 2011 · JNCI Journal of the National Cancer Institute
2. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
   Shrestha, Ritu, Prithviraj, Prashanth, Anaka, Matthew, Bridle, Kim R., Crawford, Darrell H. G., Dhungel, Bijay, Steel, Jason C., Jayachandran, Aparna · 2018 · Frontiers in Oncology
3. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
   Salman, Shaima, Meyers, David J., Wicks, Elizabeth E., Lee, Sophia N., Datan, Emmanuel, Thomas, Aline M., Anders, Nicole M., Hwang, Yousang, Lyu, Yajing, Yang, Yongkang et al. · 2022 · Journal of Clinical Investigation
4. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma
   Hassan, Manal M., Abdel-Wahab, Reham, Kaseb, Ahmed, Shalaby, Ahmed, Phan, Alexandria T., El-Serag, Hashem B., Hawk, Ernest, Morris, Jeff, Singh Raghav, Kanwal Pratap, Lee, Ju-Seog et al. · 2015 · Gastroenterology
5. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma
   Wang, Cun, Wang, Hui, Lieftink, Cor, du Chatinier, Aimee, Gao, Dongmei, Jin, Guangzhi, Jin, Haojie, Beijersbergen, Roderick L, Qin, Wenxin, Bernards, René · 2020 · Gut
6. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
   Lee, Pei-Chang, Chao, Yee, Chen, Ming-Huang, Lan, Keng-Hsin, Lee, Chieh-Ju, Lee, I-Cheng, Chen, San-Chi, Hou, Ming-Chih, Huang, Yi-Hsiang · 2020 · Cancers
7. Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis
   Dong, Bingning, Lee, Ju-Seog, Park, Yun-Yong, Yang, Feng, Xu, Ganyu, Huang, Wendong, Finegold, Milton J., Moore, David D. · 2015 · Nature Communications
8. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
   Kim, Young-Seon, Lee, Yoon-Mi, Oh, Taek-In, Shin, Dong Hoon, Kim, Geon-Hee, Kan, Sang-Yeon, Kang, Hyeji, Kim, Ji Hyung, Kim, Byeong Mo, Yim, Woo Jong et al. · 2018 · International Journal of Molecular Sciences
9. Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca2+/Calmodulin-Dependent Protein Kinase II
   Meng, Zhipeng, Li, Tao, Ma, Xiaoxiao, Wang, Xiaoqiong, Van Ness, Carl, Gan, Yichao, Zhou, Hong, Tang, Jinfen, Lou, Guiyu, Wang, Yafan et al. · 2013 · Molecular Cancer Therapeutics
10. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
    Yau, Thomas, Kaseb, Ahmed, Cheng, Ann-Lii, Qin, Shukui, Zhu, Andrew X, Chan, Stephen L, Melkadze, Tamar, Sukeepaisarnjaroen, Wattana, Breder, Valery, Verset, Gontran et al. · 2024 · The Lancet Gastroenterology & Hepatology
11. Pharmacological or transcriptional inhibition of both <scp>HDAC</scp>1 and 2 leads to cell cycle blockage and apoptosis via p21^Waf1/Cip1 and p19^INK4d upregulation in hepatocellular carcinoma
    Zhou, Hengyu, Cai, Ying, Liu, Dina, Li, Menghui, Sha, Yu, Zhang, Wenlu, Wang, Kai, Gong, Jianping, Tang, Ni, Huang, Ailong et al. · 2018 · Cell Proliferation
12. Diabetes medications and risk of HCC
    Plaz Torres, Maria Corina, Jaffe, Ariel, Perry, Rachel, Marabotto, Elisa, Strazzabosco, Mario, Giannini, Edoardo G. · 2022 · Hepatology
13. Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling
    Mleczko-Sanecka, Katarzyna, Roche, Franziska, Rita da Silva, Ana, Call, Debora, D’Alessio, Flavia, Ragab, Anan, Lapinski, Philip E., Ummanni, Ramesh, Korf, Ulrike, Oakes, Christopher et al. · 2014 · Blood
14. Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin‐2 expression in peri‐tumourous liver correlates with increased survival
    Géraud, Cyrill, Mogler, Carolin, Runge, Anja, Evdokimov, Konstantin, Lu, Shun, Schledzewski, Kai, Arnold, Bernd, Hämmerling, Günter, Koch, Philipp S., Breuhahn, Kai et al. · 2013 · Liver International
15. Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment
    Zhang, Rui, Ma, Min, Lin, Xia-Hui, Liu, Hua-Hua, Chen, Jie, Chen, Jun, Gao, Dong-Mei, Cui, Jie-Feng, Ren, Zheng-Gang, Chen, Rong-Xin · 2018 · BMC Cancer
16. STAT3 in hepatocellular carcinoma: new perspectives
    Svinka, Jasmin, Mikulits, Wolfgang, Eferl, Robert · 2014 · Hepatic Oncology
17. Non-Invasive Tumor Genotyping Using Radiogenomic Biomarkers, a Systematic Review and Oncology-Wide Pathway Analysis
    Jansen, Robin W., van Amstel, Paul, Martens, Roland M., Kooi, Irsan E., Wesseling, Pieter, de Langen, Adrianus J., Menke-Van der Houven van Oordt, Catharina W., Jansen, Bernard H.E., Moll, Annette C., Dorsman, Josephine C. et al. · 2018 · Oncotarget
18. Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development
    Cheu, Jacinth Wing-Sum, Chiu, David Kung-Chun, Kwan, Kenneth Kin-Leung, Yang, Chunxue, Yuen, Vincent Wai-Hin, Goh, Chi Ching, Chui, Noreen Nog-Qin, Shen, Wei, Law, Cheuk-Ting, Li, Qidong et al. · 2023 · Science Advances
19. United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies
    Jeong, Woondong, Doroshow, James H., Kummar, Shivaani · 2013 · Current Problems in Cancer
20. A phase 1b study of transforming growth factor‐beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
    Ikeda, Masafumi, Morimoto, Manabu, Tajimi, Masaomi, Inoue, Koichi, Benhadji, Karim A., Lahn, Michael M. F., Sakai, Daisuke · 2019 · Investigational New Drugs
21. Aflibercept in the Treatment of Metastatic Colorectal Cancer
    Wang, Tzu-Fei, Lockhart, Albert Craig · 2012 · Clinical Medicine Insights: Oncology
22. RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4
    Wang, Chun, Chen, Zhihang, Yi, Yun, Ding, Yang, Xu, Fei, Kang, Hui, Lin, Kun, Shu, Xiawen, Zhong, Zibiao, Zhang, Zhonglin et al. · 2024 · Oncogene
23. Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter
    Ding, Jia, Zhou, Xiao-Tian, Zou, Hao-Yu, Wu, Jian · 2017 · Laboratory Investigation
24. SR4 Uncouples Mitochondrial Oxidative Phosphorylation, Modulates AMP-dependent Kinase (AMPK)-Mammalian Target of Rapamycin (mTOR) Signaling, and Inhibits Proliferation of HepG2 Hepatocarcinoma Cells
    Figarola, James L., Singhal, Jyotsana, Tompkins, Joshua D., Rogers, George W., Warden, Charles, Horne, David, Riggs, Arthur D., Awasthi, Sanjay, Singhal, Sharad S. · 2015 · Journal of Biological Chemistry
25. Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma
    Wu, Jennifer, Contratto, Merly, Shanbhogue, Krishna P, Manji, Gulam A, O’Neil, Bert H, Noonan, Anne, Tudor, Robert, Lee, Ray · 2019 · World Journal of Clinical Oncology
26. Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis
    Catalá-López, Ferrán, Aleixandre-Benavent, Rafael, Caulley, Lisa, Hutton, Brian, Tabarés-Seisdedos, Rafael, Moher, David, Alonso-Arroyo, Adolfo · 2020 · Trials
27. β‐catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β‐catenin and MET
    Liang, Yan, Feng, Yun, Zong, Min, Wei, Xu‐Fu, Lee, Jin, Feng, Yukuan, Li, Hairi, Yang, Guang‐Shun, Wu, Zhong‐Jun, Fu, Xiang‐Dong et al. · 2018 · Hepatology
28. SALL4 Immunoreactivity Predicts Prognosis in Western Hepatocellular Carcinoma Patients but Is a Rare Event: A Study of 236 Cases
    Liu, Ta-Chiang, Vachharajani, Neeta, Chapman, William C., Brunt, Elizabeth M. · 2014 · American Journal of Surgical Pathology
29. Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases
    Pellegata, Natalia S., Berriel Diaz, Mauricio, Rohm, Maria, Herzig, Stephan · 2022 · Cancer and Metastasis Reviews
30. Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases
    Wen, Yankai, Ma, Lichun, Ju, Cynthia · 2023 · eGastroenterology
31. Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy
    Ray, Dipankar, Cuneo, Kyle C., Rehemtulla, Alnawaz, Lawrence, Theodore S., Nyati, Mukesh K. · 2015 · Neoplasia
32. Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Du, Qi, Yuan, Jia, Ren, Zhenggang · 2024 · Liver Cancer
33. RETRACTED ARTICLE: The Noncytotoxic Dose of Sorafenib Sensitizes Bel-7402/5-FU Cells to 5-FU by Down-Regulating 5-FU-Induced Nrf2 Expression
    Zhou, Suna, Ye, Wenguang, Duan, Xiaoyi, Zhang, Mingxin, Wang, Jiansheng · 2013 · Digestive Diseases and Sciences · Retracted
34. Recent concepts of antiangiogenic therapy
    Konno, Hiroyuki, Yamamoto, Masayoshi, Ohta, Manabu · 2010 · Surgery Today
35. Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience
    Xie, Lu, Xu, Jie, Guo, Wei, Wang, Zhen, Yao, Yang, Li, Jianmin, Lin, Jianhua, Xiao, Jianru, Yu, Xiuchun, Zhang, Weibin et al. · 2021 · Frontiers in Oncology
36. Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential
    Cheng, Clooney C. Y., Cheung, Ming Fung, Lee, Ah Young, Wu, Qiong, Chow, Savio Ho-Chit, Ang, Julie Y. J., Riquelme Medina, Ignacio, Lo, Grace, Wu, Haoran, Yang, Weiqin et al. · 2025 · Communications Biology
37. Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis
    Sun, Frances Sze Kei, Wong, Jeffrey Sum Lung, Mak, Lung-Yi, Wong, Carmen Chak-Lui, Chew, Valerie, Li, Bryan Cho Wing, Leung, Roland, Cheung, Tan To, Yau, Thomas · 2025 · Liver Cancer